Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - moxifloxacin hydrochloride 436,8 mg - eq. moxifloxacin 400 mg - film-coated tablet - 400 mg - moxifloxacin hydrochloride 436.8 mg - moxifloxacin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - moxifloxacin hydrochloride 437,5 mg - eq. moxifloxacin 400 mg - solution for infusion - 400 mg/250 ml - moxifloxacin hydrochloride 437.5 mg - moxifloxacin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - moxifloxacin hydrochloride 437,5 mg - eq. moxifloxacin 400 mg - solution for infusion - 400 mg/250 ml - moxifloxacin hydrochloride 437.5 mg - moxifloxacin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - moxifloxacin 400 mg - film-coated tablet - 400 mg - moxifloxacin 400 mg - moxifloxacin

Canada - English - Health Canada

pharmascience inc - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Canada - English - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Canada - English - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Canada - English - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials

United States - English - NLM (National Library of Medicine)

a-s medication solutions - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f

United States - English - NLM (National Library of Medicine)

a-s medication solutions - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4) ].  moxifloxacin tablets are indicated in adult patients f